Header cover image

Biotech Breakthroughs

UPDATED Apr 30, 2024

Companys with strong funding and high growth potential

15 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv YieldIndustry

IMGN *

ImmunoGen		US$268.500%96.1%US$8.4bUS$248.87PS29.1xE45.2%n/aPharmaceuticals & Biotech

ARDX *

Ardelyx		US$113.800%41.7%US$1.5bUS$238.07PS12xE59.6%n/aPharmaceuticals & Biotech

MIRM *

Mirum Pharmaceuticals		US$479.150%n/aUS$1.2bUS$894.07PS6.6xE63.2%n/aPharmaceuticals & Biotech

SGEN *

Seagen		US$3,711.480%14.0%US$35.9bUS$4,373.18PS17.5xE65.7%n/aPharmaceuticals & Biotech

HNSA N

Hansa Biopharma		kr160.750%0%kr2.5bkr573.38PS16.7xE56.9%n/aPharmaceuticals & Biotech

ZLAB N

Zai Lab		US$271.000%n/aUS$1.6bUS$900.56PS5.8xE62.0%n/aPharmaceuticals & Biotech

KRTX *

Karuna Therapeutics		US$3,226.170%n/aUS$12.2bUS$3,297.53PS18680.1xE60.0%n/aPharmaceuticals & Biotech

ORY N

Oryzon Genomics		€48.590%0%€124.4m€248.35PS7.8xE61.1%n/aPharmaceuticals & Biotech

ARGX N

argenx		€6,385.68n/an/a€20.8b€7,996.94PS17.5xE56.1%n/aPharmaceuticals & Biotech

RYTM *

Rhythm Pharmaceuticals		US$680.215.1%n/aUS$2.4bUS$1,004.60PS30.6xE60.9%n/aPharmaceuticals & Biotech

ACAD *

ACADIA Pharmaceuticals		US$509.000%60.5%US$3.8bUS$679.54PS7xE61.6%n/aPharmaceuticals & Biotech

EXAS *

Exact Sciences		US$1,141.000%n/aUS$10.9bUS$1,718.05PS4.4xE61.9%n/aPharmaceuticals & Biotech

BGNE N

BeiGene		US$2,858.160%n/aUS$14.0bUS$5,727.85PS5.7xE56.2%n/aPharmaceuticals & Biotech

ICPT *

Intercept Pharmaceuticals		US$329.000%0%US$494.0mUS$551.00PS1.7xE63.9%n/aPharmaceuticals & Biotech

ABCM N

Abcam		US$292.380%-2.5%US$3.7bUS$360.48PS8.1xE37.2%0%Pharmaceuticals & Biotech
Page 1 of 1
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.